Zimmer-Biomet deal to enter second-phase review by European Commission
MLex Summary: Medical device company Zimmer Holdings said Thursday that the company expects to receive notice on Oct. 3 that the European Commission will open a second-phase review of its planned $13.35 billion acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article